Patrys Limited
Patrys Limited
Your view on PAB.AX
Overview
What the company does, where it operates, and who runs it.
About Patrys Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Samantha South
- Headquarters
- 168 Stirling Highway, Nedlands, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Samantha South
- Headquarters
- 168 Stirling Highway, Nedlands, WA, AU
Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei.
The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers.
Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile.
Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Patrys Limited. Starting points for Patrys Limited: EPS -AUD 0.0083, beta 1.25 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Patrys Limited. Patrys Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Patrys Limited. Trailing twelve-month EPS for Patrys Limited stands at -AUD 0.0083. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrDec 2026 |
|---|---|
| Avg. estimate | AUD 0.00 |
| Low estimate | AUD 0.00 |
| High estimate | AUD 0.00 |
| No. of analysts | 0 |
| Year-ago EPS | — |
| Growth | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 |
|---|---|
| Avg. estimate | AUD 5880.00 |
| Low estimate | AUD 5880.00 |
| High estimate | AUD 5880.00 |
| No. of analysts | 1 |
| Year-ago revenue | — |
| Growth | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Patrys Limited. Patrys Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AVE.AXAvecho Biotechnology Limited | Healthcare | Biotechnology | — | ||
| BTC.AXBTC Health Limited | Healthcare | Biotechnology | — | ||
| CHM.AXChimeric Therapeutics Limited | Healthcare | Biotechnology | — | ||
| IMC.AXImmuron Limited | Healthcare | Biotechnology | — | ||
| IME.AXImExHS Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| NC6.AXNanollose Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PANCPanacos Pharmaceuticals, Inc. | Healthcare | OTC | $5,367 | ||
| PAR.AXParadigm Biopharmaceuticals Limited | Healthcare | ASX | — | ||
| PARDPoniard Pharmaceuticals, Inc. | Healthcare | OTC | $150 | ||
| PASGPassage Bio, Inc. | Healthcare | NASDAQ | $12.9M | ||
| PBIGFParadigm Biopharmaceuticals Limited | Healthcare | OTC | $87.9M | ||
| PBLAPanbela Therapeutics, Inc. | Healthcare | OTC | $53,889 | ||
| PBLSParabilis Medicines, Inc. | Healthcare | NASDAQ | $3.5B | ||
| PBMPsyence Biomedical Ltd. | Healthcare | NASDAQ | $47,738 | ||
| PBMWWPsyence Biomedical Ltd. Warrant | Healthcare | NASDAQ | $869 | ||
| PBYIPuma Biotechnology, Inc. | Healthcare | NASDAQ | $373.3M | ||
| PCSAProcessa Pharmaceuticals, Inc. | Healthcare | NASDAQ | $4.8M | ||
| PCVXVaxcyte, Inc. | Healthcare | NASDAQ | $9.3B | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Patrys Limited. Coverage tracks Patrys Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Patrys Limited.